Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Head & Neck 3

Conditions

Melanoma 116Carcinoma, Non-Small-Cell Lung 101Carcinoma, Renal Cell 67Colorectal Neoplasms 46Neoplasm Metastasis 40Squamous Cell Carcinoma of Head and Neck 38Carcinoma, Hepatocellular 38Neoplasms 35Lung Neoplasms 34Stomach Neoplasms 33Urinary Bladder Neoplasms 22Hodgkin Disease 20Carcinoma, Transitional Cell 20Brain Neoplasms 20Pancreatic Neoplasms 18Ovarian Neoplasms 18Prostatic Neoplasms 16Head and Neck Neoplasms 16Colonic Neoplasms 16Skin Neoplasms 15Sarcoma 14Glioblastoma 14Adenocarcinoma Of Esophagus 14Triple Negative Breast Neoplasms 13Carcinoma, Merkel Cell 13Small Cell Lung Carcinoma 12Rectal Neoplasms 12Esophageal Neoplasms 12Breast Neoplasms 12Uveal Melanoma 11

Interventions

pembrolizumab 5Nivolumab 3Cisplatin 3Taxes 2Paclitaxel 2poly ICLC 1fludarabine phosphate 1fludarabine 1abemaciclib 1Risk Factors 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Radiation 1Pemetrexed 1Nimorazole 1Injections 1High-Intensity Focused Ultrasound Ablation 1Erlotinib Hydrochloride 1Docetaxel 1Cyclophosphamide 1Cetuximab 1Carboplatin 1Biological Products 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neoplasms, Squamous Cell × Nivolumab × 1 year × Clear all
NCT03370276 2026-04-02

Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Completed
95 enrolled 15 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasms, Squamous Cell

NCT07460765 2026-03-10

Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)

Vanderbilt-Ingram Cancer Center

Phase 1 Not yet recruiting
40 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Mouth Neoplasms, Neoplasms, Squamous Cell

NCT06771674 2025-09-09

Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma

Hookipa Biotech GmbH

Completed
662 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡